Foslevodopa

Foslevodopa
Identifiers
	IUPAC name (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid;
CAS Number	97321-87-4;
PubChem CID	127766;
Chemical and physical data
Formula	C9H12NO7P
Molar mass	277.169 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O;
	InChI InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1; Key:YNDMEEULGSTYJT-LURJTMIESA-N;

Foslevodopa is a drug which acts as a prodrug for levodopa, originally invented in the 1980s but not developed for medical use at that time.^[1] It has more recently attracted renewed interest due to its improved pharmacokinetics compared to levodopa itself, and is now approved for use in a subcutaneous infusion as a fixed-dose combination with foscarbidopa for the treatment of Parkinson's disease, under the trade name Vyalev.^[2]^[3]

References

^ Agin PP, Sayre RM, Pawelek JM. Phosphorylated mixed isomers of L-dopa increase melanin content in skins of Skh-2 pigmented hairless mice. Pigment Cell Res. 1987;1(3):137-42. doi:10.1111/j.1600-0749.1987.tb00404.x PMID 3149738
^ Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurol Ther. 2024 Aug;13(4):1055-1068. doi:10.1007/s40120-024-00635-4 PMID 38874708
^ Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, Bray S, Dhanani S, Facheris MF, Fisseha N, Freire-Alvarez E, Hauser RA, Jeong A, Jia J, Kukreja P, Soileau MJ, Spiegel AM, Talapala S, Tarakad A, Urrea-Mendoza E, Zamudio J, Pahwa R. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance. Clin Park Relat Disord. 2024 Feb 10;10:100239. doi:10.1016/j.prdoa.2024.100239 PMID 38419617

[1] Agin PP, Sayre RM, Pawelek JM. Phosphorylated mixed isomers of L-dopa increase melanin content in skins of Skh-2 pigmented hairless mice. Pigment Cell Res. 1987;1(3):137-42. doi:10.1111/j.1600-0749.1987.tb00404.x PMID 3149738

[2] Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurol Ther. 2024 Aug;13(4):1055-1068. doi:10.1007/s40120-024-00635-4 PMID 38874708

[3] Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, Bray S, Dhanani S, Facheris MF, Fisseha N, Freire-Alvarez E, Hauser RA, Jeong A, Jia J, Kukreja P, Soileau MJ, Spiegel AM, Talapala S, Tarakad A, Urrea-Mendoza E, Zamudio J, Pahwa R. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance. Clin Park Relat Disord. 2024 Feb 10;10:100239. doi:10.1016/j.prdoa.2024.100239 PMID 38419617

[1]

[2]

[3]

Identifiers

IUPAC name (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid
CAS Number	97321-87-4
PubChem CID	127766
Chemical and physical data
Formula	C₉H₁₂NO₇P
Molar mass	277.169 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
InChI InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1 Key:YNDMEEULGSTYJT-LURJTMIESA-N